CTMX cytomx.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The stock price retrospective for CytomX Therapeutics (CTMX) demonstrates an EV/EBITDA of 0.00. CytomX Therapeutics develops solutions for the targeted destruction of tumors through collaborations with industry behemoths. The current drug portfolio minimizes side effects via the local activation of therapy. Meanwhile, the business relies on external contractors for manufacturing and testing, maintaining its status as a mobile research center.
פילוחי מדדים ואנליטיקה של חברת cytomx.com (CTMX)
CytomX Therapeutics (CTMX) develops oncology programs through external funding from strategic partners. The enterprise value to EBITDA multiple compares the total asset price to its cash flow, excluding the impact of taxes and debt load. This chart's price action allows for the filtering of market noise to assess the real value of the business. The stability of this indicator confirms the company's fundamental resilience.
